Skip to main content
Erschienen in: Rheumatology International 2/2018

24.08.2017 | Imaging

Impact of hybrid molecular imaging in retroperitoneal fibrosis: a systematic review

verfasst von: Isidora T. Grozdic Milojevic, Bogomir Milojevic, Dragana P. Sobic-Saranovic, Vera M. Artiko

Erschienen in: Rheumatology International | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

The aim of this article was to critically assess the usefulness of hybrid molecular imaging (FDG PET/CT and FDG PET/MR) procedures in the evaluation of inflammatory activity in retroperitoneal fibrosis (RPF). A systematic review of the literature was performed using PubMed without timeline restriction and using the following keywords: retroperitoneal fibrosis, disease activity, diagnostic techniques, PET/CT, PET/MR. We evaluated full text articles written in the English language. Case reports, review articles or editorials and articles not in the field of interest of this review were excluded. Nine articles comprising a total of 186 patients met the inclusion criteria and were included and described in this systematic review. The new hybrid molecular imaging methods give promising results in the evaluation of the activity of the disease, quantification and prediction of therapeutic response and in tailoring medical therapy in RPF. FDG PET/CT can be a valuable tool in detecting disease activity, particularly in asymptomatic patients with RPF with acute phase reactant increase. Hybrid imaging can predict therapy response outcome and the best time for stent removal. Although PET/MR has potential advantage in small lesions and has reduced radiation exposure in comparison to PET/CT, PET quantification parameters have potentially higher diagnostic value over MR parameters in the evaluation of RPF. Acute phase reactants alone may not be reliable for the management and follow-up assessment of the disease. Hybrid imaging in RFP could be more comfortable, more accurate, with less radiation burden than different separate imaging studies acquired at different points in time.
Literatur
1.
Zurück zum Zitat VaglioA Salvarani C, Buzio C (2006) Retroperitoneal fibrosis. Lancet 367(9506):241–251CrossRef VaglioA Salvarani C, Buzio C (2006) Retroperitoneal fibrosis. Lancet 367(9506):241–251CrossRef
2.
Zurück zum Zitat Palmisano A, Vaglio A (2009) Chronic periaortitis: a fibro-inflammatory disorder. Best Pract Res 23(3):339–353CrossRef Palmisano A, Vaglio A (2009) Chronic periaortitis: a fibro-inflammatory disorder. Best Pract Res 23(3):339–353CrossRef
4.
Zurück zum Zitat Otomi Y, Otsuka H, Terazawa K, Nose H, Kubo M, Yoneda K, Kitsukawa K, Harada M (2013) (18)F-2-fluoro-2-deoxyglucose uptake in or adjacent to blood vessel walls. J Med Invest 60(1–2):15–20CrossRefPubMed Otomi Y, Otsuka H, Terazawa K, Nose H, Kubo M, Yoneda K, Kitsukawa K, Harada M (2013) (18)F-2-fluoro-2-deoxyglucose uptake in or adjacent to blood vessel walls. J Med Invest 60(1–2):15–20CrossRefPubMed
5.
Zurück zum Zitat Yilmaz S, Tanb YZ, Ozhan M, Halac M, Asa S, Sönmezoglu K (2012) FDG PET/CT in monitoring treatment of retroperitoneal fibrosis. Rev Esp Med Nucl Imagen Mol 31(6):338–339PubMed Yilmaz S, Tanb YZ, Ozhan M, Halac M, Asa S, Sönmezoglu K (2012) FDG PET/CT in monitoring treatment of retroperitoneal fibrosis. Rev Esp Med Nucl Imagen Mol 31(6):338–339PubMed
7.
Zurück zum Zitat Mehta A, Blodgett MT (2011) Retroperitoneal Fibrosis as a cause of positive FDG PET/CT. J Radiol Case Reports 5(7):35–41CrossRef Mehta A, Blodgett MT (2011) Retroperitoneal Fibrosis as a cause of positive FDG PET/CT. J Radiol Case Reports 5(7):35–41CrossRef
8.
Zurück zum Zitat Van Bommel EF, Siemes C, Hak LE, van der Veer SJ, Hendriksz TR (2007) Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis treated with prednisone. Am J Kidney Dis 49(5):615–625CrossRefPubMed Van Bommel EF, Siemes C, Hak LE, van der Veer SJ, Hendriksz TR (2007) Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis treated with prednisone. Am J Kidney Dis 49(5):615–625CrossRefPubMed
9.
Zurück zum Zitat Monev S (2002) Idiopathic retroperitoneal fibrosis:prompt diagnosis preserves organ function. Cleve Clin J Med 69:160–166CrossRefPubMed Monev S (2002) Idiopathic retroperitoneal fibrosis:prompt diagnosis preserves organ function. Cleve Clin J Med 69:160–166CrossRefPubMed
10.
Zurück zum Zitat Bertagna F, Treglia G, Leccisotti L (2012) [18F]FDG-PET/CT in patients affected by retroperitoneal fibrosis: a bicentric experience. Jpn J Radiol 30:415–421CrossRefPubMed Bertagna F, Treglia G, Leccisotti L (2012) [18F]FDG-PET/CT in patients affected by retroperitoneal fibrosis: a bicentric experience. Jpn J Radiol 30:415–421CrossRefPubMed
11.
Zurück zum Zitat Kottra JJ, Dunnick NR (1996) Retroperitoneal fibrosis. Radiol Clin North Am 43:1259–1275 Kottra JJ, Dunnick NR (1996) Retroperitoneal fibrosis. Radiol Clin North Am 43:1259–1275
12.
Zurück zum Zitat Talati SJ, Abghari R, Kochkodan JJ, Helmer SR (1995) Use of Ga-67 imaging in diagnosis and follow-up after steroid treatment of retroperitoneal fibrosis. Clin Nucl Med 20:995–997CrossRefPubMed Talati SJ, Abghari R, Kochkodan JJ, Helmer SR (1995) Use of Ga-67 imaging in diagnosis and follow-up after steroid treatment of retroperitoneal fibrosis. Clin Nucl Med 20:995–997CrossRefPubMed
13.
Zurück zum Zitat Treglia G, Mattoli MV, Bertagna F, Giubbini R, Giordano A (2013) Emerging role of Fluorine-18-fluorodeoxy glucose positron emission tomography in patients with retroperitoneal fibrosis: a systematic review. Rheumatol Int 33:549–555CrossRefPubMed Treglia G, Mattoli MV, Bertagna F, Giubbini R, Giordano A (2013) Emerging role of Fluorine-18-fluorodeoxy glucose positron emission tomography in patients with retroperitoneal fibrosis: a systematic review. Rheumatol Int 33:549–555CrossRefPubMed
14.
Zurück zum Zitat Nakajo M, Jinnouchi S, Tanabe H, Tateno R, Nakajo M (2007) 18F-fluoro deoxyglucose positron emission tomography features of idiopathic retroperitoneal fibrosis. J Comput Assist Tomogr 31(4):539–543CrossRefPubMed Nakajo M, Jinnouchi S, Tanabe H, Tateno R, Nakajo M (2007) 18F-fluoro deoxyglucose positron emission tomography features of idiopathic retroperitoneal fibrosis. J Comput Assist Tomogr 31(4):539–543CrossRefPubMed
15.
Zurück zum Zitat Piccoli GB, ConsiglioV Arena V, Pelosi E, Anastasios D, Ragni F, Fiori C, Cortese G, Deagostini MC, Porpiglia F, Scarpa RM (2010) Positron emission tomography as a tool for the‘tailored’management of retroperitoneal fibrosis: a nephro-urological experience. Nephrol Dial Transpl 25(8):2603–2610CrossRef Piccoli GB, ConsiglioV Arena V, Pelosi E, Anastasios D, Ragni F, Fiori C, Cortese G, Deagostini MC, Porpiglia F, Scarpa RM (2010) Positron emission tomography as a tool for the‘tailored’management of retroperitoneal fibrosis: a nephro-urological experience. Nephrol Dial Transpl 25(8):2603–2610CrossRef
16.
Zurück zum Zitat Guignard R, Simukoniene M, Garibotto V, Ratib O (2012) 18F-FDG PET/CT and contrast-enhanced CT in a one-stop diagnostic procedure: a better strategy for management of patients suffering from retroperitoneal fibrosis? Clin Nucl Med 37(5):453–459CrossRefPubMed Guignard R, Simukoniene M, Garibotto V, Ratib O (2012) 18F-FDG PET/CT and contrast-enhanced CT in a one-stop diagnostic procedure: a better strategy for management of patients suffering from retroperitoneal fibrosis? Clin Nucl Med 37(5):453–459CrossRefPubMed
17.
Zurück zum Zitat Moroni G, Castellani M, Balzani A, Dore R, Bonelli N, Longhi S, Martinelli I, Messa P, Gerundini P (2012) The value of 18FFDG PET/CT in the assessment of active idiopathic retroperitoneal fibrosis. Eur J Nucl Med Mol Imaging 39:1635–1642CrossRefPubMed Moroni G, Castellani M, Balzani A, Dore R, Bonelli N, Longhi S, Martinelli I, Messa P, Gerundini P (2012) The value of 18FFDG PET/CT in the assessment of active idiopathic retroperitoneal fibrosis. Eur J Nucl Med Mol Imaging 39:1635–1642CrossRefPubMed
18.
Zurück zum Zitat Fofi C, Prosperi D, Pettorini L, Festuccia F, Pirisino R, Lanni V, Scopinaro F, Punzo G, Menè P (2016) Diagnosis and follow-up of idiopathic retroperitoneal fibrosis: role of (18)F-FDG-PET/CT and biochemical parameters in patients with renal involvement. Intern Emerg Med 11(6):809–816CrossRefPubMed Fofi C, Prosperi D, Pettorini L, Festuccia F, Pirisino R, Lanni V, Scopinaro F, Punzo G, Menè P (2016) Diagnosis and follow-up of idiopathic retroperitoneal fibrosis: role of (18)F-FDG-PET/CT and biochemical parameters in patients with renal involvement. Intern Emerg Med 11(6):809–816CrossRefPubMed
19.
Zurück zum Zitat Ruhlmann V, Poeppel TD, Brandt AS, Grüneisen J, Ruhlmann M, Theysohn JM, Forsting M, Bockisch A, Umutlu L (2016) (18)F-FDG PET/MRI evaluation of retroperitoneal fibrosis: a simultaneous multiparametric approach for diagnosing active disease. Eur J Nucl Med Mol Imaging. 43(9):1646–1652CrossRefPubMed Ruhlmann V, Poeppel TD, Brandt AS, Grüneisen J, Ruhlmann M, Theysohn JM, Forsting M, Bockisch A, Umutlu L (2016) (18)F-FDG PET/MRI evaluation of retroperitoneal fibrosis: a simultaneous multiparametric approach for diagnosing active disease. Eur J Nucl Med Mol Imaging. 43(9):1646–1652CrossRefPubMed
20.
Zurück zum Zitat Fernando A, Pattison J, Horsfield C, D’Cruz D, Cook G, O’Brien T (2016) [18F]-fluorodeoxyglucose positron emission tomography in the diagnosis, treatment stratification, and monitoring of patients with retroperitoneal fibrosis: a prospective clinical study. Eur Urol. doi:10.1016/j.eururo.2016.10.046 PubMed Fernando A, Pattison J, Horsfield C, D’Cruz D, Cook G, O’Brien T (2016) [18F]-fluorodeoxyglucose positron emission tomography in the diagnosis, treatment stratification, and monitoring of patients with retroperitoneal fibrosis: a prospective clinical study. Eur Urol. doi:10.​1016/​j.​eururo.​2016.​10.​046 PubMed
21.
Zurück zum Zitat Thuermel K, Einspieler I, Wolfram S, Moog P, Meier R, Schwaiger M, Heemann U (2017) Disease activity and vascular involvement in retroperitoneal fibrosis: first experience with fully integrated 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging compared to clinical and laboratory parameters. Clin Exp Rheumatol 35 Suppl 103(1):146–154PubMed Thuermel K, Einspieler I, Wolfram S, Moog P, Meier R, Schwaiger M, Heemann U (2017) Disease activity and vascular involvement in retroperitoneal fibrosis: first experience with fully integrated 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging compared to clinical and laboratory parameters. Clin Exp Rheumatol 35 Suppl 103(1):146–154PubMed
22.
Zurück zum Zitat Brix G, Lechel U, Glatting G, Ziegler SI, Münzing W, Müller SP, Beyer T (2005) Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med 46(4):608–613PubMed Brix G, Lechel U, Glatting G, Ziegler SI, Münzing W, Müller SP, Beyer T (2005) Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med 46(4):608–613PubMed
23.
Zurück zum Zitat Tonkopi E, Ross AA, MacDonald A (2013) Journal club: CT dose optimization for whole-body PET/CT examinations. AJR Am J Roentgenol 201(2):257–263CrossRefPubMed Tonkopi E, Ross AA, MacDonald A (2013) Journal club: CT dose optimization for whole-body PET/CT examinations. AJR Am J Roentgenol 201(2):257–263CrossRefPubMed
24.
Zurück zum Zitat Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE (1999) Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 33(5):829–839CrossRefPubMed Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE (1999) Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 33(5):829–839CrossRefPubMed
Metadaten
Titel
Impact of hybrid molecular imaging in retroperitoneal fibrosis: a systematic review
verfasst von
Isidora T. Grozdic Milojevic
Bogomir Milojevic
Dragana P. Sobic-Saranovic
Vera M. Artiko
Publikationsdatum
24.08.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 2/2018
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-017-3798-y

Weitere Artikel der Ausgabe 2/2018

Rheumatology International 2/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.